<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLAVOXATE HYDROCHLORIDE</span><br/>(fla-vox'ate)<br/><span class="topboxtradename">Urispas<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">antispasmodic</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Exerts spasmolytic (papaverine-like) action on smooth muscle. Reported to produce an increase in urinary bladder capacity
         in patients with spastic bladder, possibly by direct action on detrusor muscle. Also demonstrates local anesthetic and analgesic
         action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Has antispasmotic action on the urinary bladder.</p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic relief of dysuria, frequency, urgency, nocturia, incontinence, and suprapubic pain associated with various urologic
         disorders.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pyloric or duodenal obstruction, obstructive intestinal lesions, ileus, achalasia, GI hemorrhage; obstructive uropathies of
         lower urinary tract. Safety during pregnancy (category C) or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Suspected glaucoma.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Dysuria, Nocturia, Incontinence</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100200 mg t.i.d. or q.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give without regard to meals.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, vertigo, drowsiness, mental confusion (especially in older adults). <span class="typehead">CV:</span> Palpitation, tachycardia. <span class="typehead">Special Senses:</span> Blurred vision, increased intraocular tension, disturbances of eye accommodation. <span class="typehead">GI:</span> Nausea, vomiting, dry mouth (and throat), constipation (with high doses). <span class="typehead">Skin:</span> Dermatosis, urticaria. <span class="typehead">Other:</span> Dysuria, hyperpyrexia, eosinophilia, leukopenia (rare). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May antagonize the GI motility effects of <b>metoclopramide.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Elimination:</span> 1030% excreted in urine within 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor heart rate. Take apical pulse for 1 full minute. Report tachycardia.</li>
<li>Lab tests: Obtain periodic evaluation of blood counts during therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Report adverse reactions to physician as well as clinical improvement or the lack of a favorable response.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>